Iovance Biotherapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, everyone. My name is [Antoine Natale], and I'm a member of the JPMorgan health care investment banking team. Thank you all for joining us today. It is my pleasure to introduce Maria Fardis, President and CEO of Iovance.
As a reminder, you may submit questions through the ask-a-question feature, which is listed under the presentation on the website. We would advise you to submit your questions live during the session, and they will be answered at the end.
Maria, back to you.
Thank you, Antoine. Good morning. I will be speaking about tumor-infiltrating100 lymphocyte cell therapy for treatment of solid tumors.
I'm moving to Slide 2, where our forward-looking statements is noted. We are a public company, so I draw your attention to those statements.
On Slide 3, we're showing you what is the goal for the company. As I noted, this is a cell therapy company for treatment of solid tumors. We aim to bring TIL therapy into
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |